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Abstract
Background: Recommended treatment for severe rabies exposure in unvaccinated individuals includes wound cleaning,
administration of rabies immunoglobulins (RIG), and rabies vaccination. We conducted a survey of rabies treatment
outcomes in the Philippines.
Methods: This was a case series involving 7,660 patients (4 months to 98 years of age) given purified equine RIG (pERIG) at
the Research Institute for Tropical Medicine (Muntinlupa, Philippines) from July 2003 to August 2004 following Category II or
III exposures. Data on local and systemic adverse reactions (AR) within 28 days and biting animal status were recorded;
outcome data were obtained by telephone or home visit 6–29 months post-exposure.
Results: Follow-up data were collected for 6,464 patients. Of 151 patients with laboratory-confirmed rabies exposure, 143
were in good health 6–48 months later, seven could not be contacted, and one 4-year-old girl died. Of 16 deaths in total, 14
were unrelated to rabies exposure or treatment. Two deaths were considered PEP failures: the 4-year old girl, who had
multiple deep lacerated wounds from a rabid dog of the nape, neck, and shoulders requiring suturing on the day of
exposure, and an 8-year-old boy who only received rabies PEP on the day of exposure.
Conclusions: This extensive review of outcomes in persons with Category III exposure shows the recommended treatment
schedule at RITM using pERIG is well tolerated, while survival of 143 laboratory-confirmed rabies exposures confirms the
intervention efficacy. Two PEP intervention failures demonstrate that sustained education and training is essential in rabies
management.
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Introduction
Rabies is a zoonotic disease characterized by progressive and
incurable viral encephalitis, invariably fatal if untreated and
usually transmitted by the bite(s) or scratches of an infected
animal. Data from the Department of Health show that every
year, over 100,000 people at risk in the Philippines receive rabies
post-exposure prophylaxis (PEP), which varies according to the
categorization of the exposure as defined by the World Health
Organization (Table 1). The most severe cases, Category III,
require wound cleaning, rabies vaccination, and direct wound
infiltration with rabies immunoglobulin (RIG) and where possible,
observation of the biting animal if it does not already display
clinical symptoms of rabies for a period of 10 days [1,2].
Infiltration of RIGs into the wound(s) is essential in the
management of severe bites to provide passive antibody protection
during the first 1–2 weeks while the body develops its own
immune response to vaccination. The WHO recommends the use
of human RIG (HRIG) or equine (ERIG) in category III exposures
[2]. For multiple severe Category III exposure HRIG is
recommended, however, when not available or accessible, ERIG
or pERIG must be used. As availability of HRIG is constrained by
the limited production capacities imposed when using human
plasma as the immunoglobulin source, bite victims in highly
endemic countries are more likely to receive ERIG or pERIG.
F(ab’)2 fragment rabies immunoglobulin (Favirab, Sanofi
Pasteur, Lyon, France) is a highly purified pERIG, characterized
in animal models [3] and in humans [4] and is currently used in
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in a product with a high purity with selective extraction of active
immunoglobulin molecules (IgG) from plasma and a final
purification of F(ab’)2 from the IgG peptic digest. The final
pasteurized solution for wound infiltration has a high specific
activity, containing mainly F(ab’)2 molecules (85%). The clearance
of Favirab is more rapid than ERIG and HRIG, documented by
certain experimental animal data, however, this is not considered
to influence the efficacy. Fewer than 1% of patients report adverse
events to Favirab, these consisting mainly of mild allergic type
reactions.
We report the results of a review of consultation records and
follow-up investigations to determine the health status of persons
who received PEP, including Favirab as a source of ERIG, at the
Research Institute of Tropical Medicine, Manila.
Materials and Methods
For the purpose of this case series, only records of patients given
commercial lots of pERIG (Favirab) at the Research Institute of
Tropical Medicine (RITM) rabies Admitting Section from July
2003 to August 2004 were analyzed. RITM is a government
research institution that serves as a major referral center for rabies
and animal bite patients. The study was approved by the RITM
Institutional Review Board. A verbal consent was obtained from
the patient or parents/guardians of children immediately prior to
the follow-up interview.
Patient records were retrieved from the Medical Records
Department and reviewed by trained research assistants (under
supervision of BQ). It was anticipated that some records could
not be interpreted because of incomplete information contained
in the patient’s records, record loss or, simply, illegible
handwriting. Data were transcribed on a standard data collection
form developed for the study and included information on
demographics, rabies exposure, animal status and/or laboratory
investigation of the animal, rabies PEP including skin testing
data, timing of pERIG and rabies vaccine administration, tetanus
prophylaxis and local and systemic adverse reactions (ARs)
occurring up to 28 days from the administration of pERIG. ARs
were categorized as either not related or possibly, probably or
definitely related. Skin testing was performed by intradermal (ID)
administration of 0.1 mL of 1:10 solution of pERIG and read
after 15 minutes. A repeat skin test was performed in the event a
result was positive or doubtful.
The pERIG dose was calculated at a dose of 40 iu/kg,
infiltrated around the wounds. At the time of the case series study,
any remaining pERIG was injected intramuscularly in the
buttocks. Beginning November 2004, the recommendation on
the administration of the remaining volume of the pERIG was
modified and remaining pERIG was injected intramuscularly on
the anterior thigh. The recommended rabies vaccination regimen
was day 0, 3, 7, 28 and 90. Three different rabies vaccines were
used, 99.1% Verorab vaccine, 0.7% Rabipur vaccine and 0.2%
Lyssavac vaccine.
To document post-treatment health status, patients or parents/
guardians of children were contacted either by telephone or by a
home visit at least six months from the time of the bite.
Rabies investigations
Whenever possible, as part of standard treatment procedures,
and in order to confirm the presence of rabies virus in biting
animals that had died or were killed, a direct Fluorescent Antibody
Test (dFAT) was performed at the rabies laboratory of the RITM
following standard procedures [5].
Author Summary
Infection from a bite by a rabid animal is fatal unless rapid
treatment (thorough cleaning of the wound, administra-
tion of rabies immunoglobulins (RIG), and a full anti-rabies
vaccination course) is provided. Ideally human RIG should
be used, but cheaper, more readily available purified horse
RIG (pERIG) are widely used in developing countries.
Follow-up of over 7,600 patients previously given pERIG at
the rabies treatment reference center in Manila (Philip-
pines) provided updated health status for 6,458 patients
39 days to 29 months after treatment. A total of 151
patients had been bitten by animals with laboratory-
confirmed rabies. Two rabies deaths were reported, one in
a 4-year-old girl with bites on the back, shoulder, and neck
so severe that stitching was required to prevent bleeding
(against recommended practice), and another in an 8-year-
old boy who only received rabies vaccination on the day of
initial treatment. A 7-year-old cousin of this boy, bitten by
the same animal, who did receive the full vaccination
course was still healthy 10 months later. Fourteen other
reported deaths had causes unrelated to rabies. These data
illustrate the effectiveness of pERIG as part of the
recommended treatment regimen, while highlighting the
importance of adhering to current recommendations.
Table 1. WHO recommendations for suspected rabies post-exposure treatment [2].
Category
Type Of Contact With A Wild Or Domestic Animal Presumed
To Be Rabid Or With Confirmed Rabies, Or An Animal Which
Cannot Be Placed Under Observation Recommended Treatment
I Touching or feeding of animals; or licks on intact skin None, if reliable case history is available
II Nibbling of uncovered skin; or minor scratches or abrasions without
bleeding
Administer vaccine immediately
Stop treatment if animal remains healthy throughout an observation
period of 10 days
* or if animal is proven to be negative for rabies by a
reliable laboratory using appropriate diagnostic techniques
III Single or multiple transdermal bites; or Scratches and licks on broken skin
Contamination of mucous membrane with saliva (i.e., licks)
Exposures to bats
Administer rabies immunoglobulin and vaccine immediately.
Stop treatment if animal remains healthy throughout an observation
period of 10 days or if animal is found to be negative for rabies by a
reliable laboratory using appropriate diagnostic techniques
*In Philippines, the recommended duration of the observation period is 14 days.
doi:10.1371/journal.pntd.0000243.t001
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A total of 7,660 records of subjects having received pERIG at
the time of their potential rabies exposure during the period July
2003 to August 2004 could be retrieved and were reviewed for this
study; 3,502 (45.7%) subjects came from the Metro Manila area,
3,382 (44.2%) subjects came from the four neighboring provinces,
Bulacan (in the north) Rizal (in the East), Cavite and Laguna (in
the south) and the remaining 776 (10.1%) from other provinces as
far as Camarines Norte located 350 km south of Metro Manila.
The most affected age group was the under -10’s, in which almost
twice as many boys as girls were treated, and overall 61.8% of the
cases reported were in children less than 15 years of age. The
length of follow-up varied between 35 days and 29 months.
Review of data contained in the patient’s records at RITM
pERIG administration. The results of skin testing prior to
pERIG administration were documented for 7,495 subjects
(97.8% of the study population). A positive result (erythema
$6 mm) was found in five subjects (0.07%) and inconclusive
results were recorded for three subjects, but all 8 subjects were
negative upon repeat testing and no hypersensitivity reactions
were noted following the administration of pERIG.
The route of administration of pERIG was documented in
7,639 subjects (99.7%); combined wound infiltration and intra-
muscular injection in 7,470 (97.5%) subjects, infiltration into the
wounds alone in 108 (1.4%) subjects, and intramuscular injection
only in 61 subjects (0.8%).
Rabies vaccination and tetanus prophylaxis. A total of
7,542 subjects (98.5%) received rabies vaccine on Day 0: 6,609
subjects (86.5%) by the intradermal (ID) route and 121 (1.6%)
subjects by the intramuscular (IM) route, the route of
administration not being documented in 796 (10.4%) records.
The RITM records could only provide data on 4,118 (53.8%)
subjects having received their second dose of vaccine on day 3, and
3,329 (43.5%) subjects having received their third dose on day 7.
On day 28, 2,410 (31.5%) subjects returned for the 4
th dose and
687 (9.0%) subjects returned for the 5
th dose on day 90. It could
not be ascertained whether 118 (1.5%) subjects with missing data
received rabies vaccine elsewhere. These rabies vaccination data at
RITM should be interpreted with caution and not regarded as a
‘lack of compliance’ or interpreted to suggest that fewer doses of
vaccine are acceptable (or capable of conferring a high degree of
protection), as patients frequently returned to their local
community animal bite centers for follow-up vaccinations; hence
information on subsequent doses would not have been entered into
the RITM records.
Tetanus prophylaxis was provided to 6,342 (82.9%) subjects, as
either tetanus toxoid or DTP vaccination, with administration of
anti-tetanus serum in 5,652 (73.8%) subjects.
Safety. Of the 7,660 pERIG-treated subjects, local and
systemic adverse reactions (AR) were documented in 35 (0.46%)
and 104 (1.36%) subjects, respectively. Only 2 (0.03%) subjects
had documented local ARs within 30 minutes post-vaccination
and 11 (0.14%) subjects were documented as experiencing possible
allergic reactions, such as dizziness, drowsiness, hypersensitivity
reaction, itchiness, loss of consciousness and/or rash on the day of
vaccinations. A total of 29 local and 90 systemic ARs were
considered possibly, probably or definitely related to the pERIG
and/or rabies vaccine administration. In addition, at the time of
the survey, subjects reported on their ‘current’ medical condition.
A total of 19 medical conditions were reported – nine general
conditions, (e.g., influenza, fever), three subjects with cancer, two
subjects with nervous system disorders, i.e., stroke and paralysis,
two subjects with respiratory disorders, one liver disease, one
kidney disease and one diabetes mellitus. When contact was
attempted with the subject with paralysis in February 2007 to
document his condition, we discovered that this 58-year-old man
had died of complications of end-stage renal failure and diabetes
mellitus.
Animal data. A total of 6,528 records (85.2%) reported data
on the source of animal exposure. The most frequently identified
animals associated with bites were dogs (73.2%), followed by cats
(11.2%), other animals (0.54%), or combined dog and cat (0.05%).
It is notable that 23 subjects (0.3%) received treatment after
exposure to rabies-infected humans.
After a 14 day post-exposure observation period 3,922 (60.0%)
animals were alive and considered normal; 1,561 (23.9%) animals
died or were killed and the health status of the remaining animals
could not be documented.
Data obtained during the follow-up investigations
During follow-up investigations (by telephone, by home visit or
by hospital record) a total of 7,604 (99.3%) subjects could be
contacted as 56 subjects moved out of the area or their contact
address or telephone number were inadequate. A total of 3,970
(51.8%) subjects were contacted by telephone, 3,595 (46.9%)
subjects by home visit and 18 (0.23%) by telephone followed by a
home visit.
Health status could be documented in 6,468 (84.8%) subjects,
but for 1,164 (15.3%) subjects no follow-up information was
obtained as they had moved from the original address, etc. The
interval between PEP-and follow-up event varied between 35 days
and 29 months.
Data on deaths. There were 16 deaths in the whole study
population, two of which were considered rabies PEP intervention
failures. The other 14 fatalities were considered not to be related to
either rabies infection or PEP – seven due to cardiac conditions,
two gastro-intestinal conditions, two cases of stroke, one case each
of diabetes mellitus, tuberculosis, kidney failure and car accident.
The time interval of the reported deaths varied between 35 days
and 16 months (with a mean of 7.4 months).
The clinical course of the first rabies fatality is summarized in
Figure 1. Briefly, a 4-year-old malnourished girl was presented to
the RITM 1K hours after being attacked by a dog which had to
be forcefully separated from the child by an uncle (who was also
bitten). She had multiple deep lesions on the shoulder, back and
nape. Immediate treatment consisted of wound washing, wound
infiltration with diluted pERIG and intramuscular injection of the
remaining volume, and rabies vaccine by ID route. Before
returning home, the wounds were sutured because of their severity
and continued bleeding. She received subsequent doses of rabies
vaccine ID as scheduled. On day 24, however, she was
hospitalized at RITM with signs and symptoms of rabies and
died 55 days post-exposure.
On October 21
st 2003 the second case, an 8-year-old boy (from
Laguna) was bitten by a pet dog and seen at RITM the same day
with a Category III single laceration of the right eyelid. He
received pERIG, partly infiltrated around the wound with the
remaining volume administered IM in the buttocks (precise
volume not recorded) and a first dose of rabies vaccine (0.1 mL
ID in both deltoids). He also received anti-tetanus serum (3,000 IU
IM), tetanus toxoid (0.5 mL IM) and cloxacillin (125 mg/mL,
11 mL every 6 hours). It was not documented whether wound
cleaning was performed. A 7-year-old cousin bitten by the same
dog resulting in a similar facial lesion received the same day 0
treatment. Both children returned with their parents to their home
towns in Laguna. On November 20
th 2003, the 8-year-old boy
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doi:10.1371/journal.pntd.0000243.g001
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practitioner. Five days later he was seen at the RITM Emergency
Ward with restlessness, irritability and increased salivation. During
consultation, hydrophobia and aerophobia could be elicited. The
history revealed the boy had not received any further doses of
rabies vaccine. The family refused hospital admittance; the boy
died at home and was buried the same day, so no post-mortem
investigations were conducted. No laboratory investigations on the
animal had been initiated either. During follow-up contacts it was
reported that the surviving 7-year-old cousin had completed the
course of rabies vaccination until day 90 and was in good health
10.5 months later.
Data on laboratory confirmed rabies infection in
animals. The remains of 252 animals, which together had
inflicted wounds in 266 subjects, were tested for rabies virus
infection by dFAT at RITM; 137 animals were rabies-positive; 96
were rabies-free and 19 were inconclusive.
Data on health status of subjects exposed to proven rabid
animals. None of the 96 rabies-free animals inflicted wounds in
more than one person, but attacks by the 137 rabies positive
animals resulted in exposures of 151 subjects. The ages of these
151 individuals varied from 1 to 72 years with 68 (45%) being
children less than 9 years of age. Whereas 149 (98.7%) of these
subjects received pERIG by infiltration and IM administration,
one subject received pERIG by infiltration alone and one received
pERIG by by IM injection in the buttock since exposure consisted
of kissing a rabid dog. A total of 147 (97.4%) subjects received a
first dose of rabies vaccine, 82% by the ID route.
The health status was documented during the study survey
period in 139 subjects with a mean observation period of
12.5 months (min 56 days–max 27 months). During the review
process in February 2007, further attempts to identify and contact
the remaining 12 subjects were made, including a review of
national and regional rabies death registries, municipality death
registries and discussions with officers of regional epidemiology
surveillance units. We were then able to document survival and
good health status in an additional five subjects, yielding a new
total of 144 healthy subjects with a maximum observation period
of 4 years. The remaining seven subjects could not be contacted;
however, their names were not identified in the different death
registries.
For comparison, in the group of 96 subjects bitten by
laboratory-proven rabies-free animals, 86 persons were healthy
and two subjects died; a 55-year-old man died of complications of
diabetes 284 days post-exposure and a 37- year-old woman who
died of a myocardial infarction 169 days post-exposure. Eight
persons (8.3%) were lost to follow-up in this rabies-free group, a
higher proportion than those lost to follow-up in the rabies-positive
exposure group, (7/151, 4.6%) and only half of those lost to
follow-up in the total population of the retrospective study
(15.3%).
Location of the bites. The location and characteristics of the
bites documented in subjects bitten by dFAT rabies-positive
animals is summarized in Table 2, with over 54% of the bites in
the richly innervated regions of head, hands or foot. Of the 138
subjects bitten in one body site, 68 (49%) suffered multiple wounds
due to repeated biting by the rabid animal.
Discussion
This primary objective of the evaluation was to document the
health status of subjects given rabies PEP which included use of the
purified equine rabies immunoglobulin (pERIG), Favirab. The
health status of patients treated after Category II/III exposure
with the standard of care described in the RITM guidelines was
documented by an active survey by telephone or home visits. The
RITM guidelines are in accordance with the WHO guidelines
[2,6], the local Philippine recommendations and those developed
in other countries [7].
Not unexpectedly, exposure was seen predominantly in children
5 years or younger, with over 23.28% of exposures occurring
below 5 years of age; twice as many boys exposed when compared
to girls. A similar age and sex distribution was reported in
Thailand [8], although the age distribution was different to that
recently reported in India [9].
The records made no reference to washing of the wounds,
however, the standard recommendations of the RITM are likely to
have been implemented carefully. Attending staff of the different
animal bite treatment centers are trained in the appropriate
management of patients with animal bites and those with Category
III exposure are referred to the RITM Admitting Section. Wound
washing is followed by an infiltration of pERIG into the wound
site and injection of the remaining pERIG by IM route. This split
administration was documented in 97.8% of the cases, only 108
cases (1.4%) having pERIG infiltration into the wound alone. 61
patients received pERIG by IM only; 16 of whom were exposed to
rabid patients and 6 had healed wounds at the time of the
consultation.
Over 54% of subjects had exposure in highly innervated body
regions, such as the head, hands or feet, and one 23-year-old
subject was bitten on the penis. Specific reference to exposure
involving fingers or toes was documented in 24 subjects (2–
61 years-old) and following treatment, no compartment syndrome
was reported. This experience is similar to that observed in
Thailand [10].
A first dose of rabies vaccine was administered to 98.5% of the
study population. Rabies vaccination for the second and third dose
Table 2. Details of the body localization of the wounds
inflicted by dFAT positive animals in one body site or at
multiple sites in the body.
Body site # Total %
One Multiple
Head 10 5 15 9.9
Upper Limb 53 7 60 39.7
arm 4 3 7 4.6
upper arm 2 0 2 1.3
lower arm 10 2 12 7.9
hand 37 2 39 25.8
Trunk 90 9 6 . 0
thorax 3 0 3 2.0
abdomen/penis 2 0 2 1.3
back, shoulder 3 0 3 2.0
buttock 1 0 1 0.7
Lower Limb 66 1 67 44.4
leg 21 1 22 14.6
thigh 10 0 10 6.6
lower leg 7 0 7 4.6
foot 28 0 28 18.5
Total 138 13 151 100
doi:10.1371/journal.pntd.0000243.t002
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and 43.5%, respectively. During the follow-up investigation, data
on rabies vaccination in local animal bite treatment centers was
not requested to avoid introducing a recall bias.
For the 6,468 subjects for whom follow-up information was
obtained, the mean interval between exposure and follow-up was
11.5 months (ranging from 35 days to 29 months). During the
survey window, 16 deaths were recorded in the whole study
popualtion, in subjects from 4 to 72 years of age, occurring
between 35 days and 16 months following exposure. The causes of
14 deaths were clearly identified as being unrelated to the rabies
exposure, but two deaths were considered PEP intervention
failures. Other clinical conditions reported by the patients or their
parents occurred between 8 and 28 months but none were
considered related to the treatment.
The documented healthy outcome of 143 subjects exposed to
laboratory-proven rabid animals showed that the combination of
pERIG, rabies vaccine and wound treatment is effective in
protecting against canine rabies virus infection. The results
confirm the clinical effectiveness of pERIG when used in PEP,
notwithstanding the questions raised by scientific research, such as
a more rapid clearance and a reported difference in protection
associated with the use of pERIG against different rabies strains in
animal models [11].
Nonetheless, no treatment intervention is 100% successful as
illustrated by two tragic outcomes. The first case concerned a
malnourished girl with severe lacerations in critical anatomical
areas [12]. She was the first bite victim of the dog, and therefore
probably received a large inoculum of the virus in highly
innervated areas. Further, given her extensive lacerations with
persistent bleeding, her wounds were sutured. She did subse-
quently develop an adequate immune response to the vaccine, as
described for other malnourished children [13], but still suc-
cumbed to the rabies infection (Figure 1). The WHO recommen-
dations (TRS931) state that in cases of multiple severe exposures,
HRIG if available should be infiltrated in the wounds, otherwise
pERIG should be used and a maximum quantity must be
infiltrated undiluted in the lesions. We can only speculate whether
the use of HRIG, or indeed refraining from suturing the wounds,
could have prevented the course of disease in this case. The second
case concerned a boy who only received treatment on the day he
was bitten by a rabid dog, although this was not confirmed. With
no subsequent vaccinations the boy died. What is notable in this
case is that a cousin bitten by the same animal on the same day,
and who completed the recommended rabies vaccination series
through 90 days, was in good health 10 months post exposure.
These two cases are defined as rabies PEP intervention failures.
In summary, records of 7,660 patients given rabies PEP at the
RITM during the period July 2003 to August 2004 were
considered in this case series. Although the true extent of rabies
exposure in all 7,660 patients is unknown, of 144 cases of
laboratory-proven rabies Category III exposure available for
follow-up, there was one rabies PEP intervention failure. A second
presumed PEP intervention failure, there being no confirmation of
rabies infection in the biting animal, highlights the importance of
the potential of rabies infection by animals not being examined for
their rabies status and illustrates that the burden of disease is more
important.
Thus, the RITM rabies PEP guidelines, i.e., wound cleaning and
treatment, antibiotic and tetanus prophylaxis, rabies vaccination
and use of pERIG for Category III exposures by potential rabid
animals are deemed satisfactory. Whereas further consideration of
the development of alternative treatments to the current RIGs,
such as monoclonal antibodies, is merited [11], the real-world,
clinical experience presented here emphasizes that, in the
meantime, correct implementation of the rabies prevention
recommendations is of paramount importance to save lives.
Continued training of treating physicians and attending staff
should further improve the quality of treatment and care.
Extensive lesions in highly innervated body regions are of
particular concern and may demand specific clinical interventions,
such as immediate suturing. It must be borne in mind that such
deviations from the recommendations are often basic and
unavoidable when working under field conditions, and must be
considered with great caution when interpreting unexpected
outcomes. The experience from the RITM is that pERIG, when
administered as recommended and as part of the rabies PEP in
conjunction with wound treatment and rabies vaccination, is safe
and effective and contributes to the prevention of otherwise fatal
consequences of rabies infection.
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